Armistice Capital LLC bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 49,762 shares of the medical equipment provider's stock, valued at approximately $5,020,000.
Several other institutional investors and hedge funds also recently modified their holdings of BSX. Brighton Jones LLC boosted its position in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after buying an additional 226 shares during the period. Bank Pictet & Cie Europe AG boosted its holdings in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Highview Capital Management LLC DE boosted its holdings in Boston Scientific by 6.2% in the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock valued at $2,189,000 after purchasing an additional 1,439 shares during the last quarter. Aptus Capital Advisors LLC boosted its holdings in Boston Scientific by 17.3% in the fourth quarter. Aptus Capital Advisors LLC now owns 11,692 shares of the medical equipment provider's stock valued at $1,044,000 after purchasing an additional 1,723 shares during the last quarter. Finally, Algert Global LLC purchased a new position in Boston Scientific in the fourth quarter valued at about $297,000. Hedge funds and other institutional investors own 89.07% of the company's stock.
Boston Scientific Stock Up 0.7%
NYSE BSX traded up $0.72 on Wednesday, hitting $107.38. 7,518,463 shares of the stock traded hands, compared to its average volume of 5,622,467. The stock has a 50-day moving average of $104.71 and a 200 day moving average of $102.18. Boston Scientific Corporation has a twelve month low of $80.50 and a twelve month high of $108.94. The company has a market capitalization of $159.10 billion, a P/E ratio of 63.91, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.
Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research analysts recently commented on BSX shares. Leerink Partners started coverage on Boston Scientific in a report on Monday, June 16th. They issued an "outperform" rating and a $118.00 price target for the company. Wells Fargo & Company increased their price target on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Citigroup reissued a "buy" rating and issued a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Raymond James Financial increased their price target on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a report on Thursday, July 24th. Finally, Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average price target of $117.50.
Read Our Latest Report on Boston Scientific
Insider Buying and Selling
In other news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. This represents a 58.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock valued at $18,397,457 over the last quarter. Company insiders own 0.50% of the company's stock.
About Boston Scientific
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Read More
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
